NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia by Lopez-Millan, Belen et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute
lymphoblastic leukemia
Lopez-Millan, Belen ; Sanchéz-Martínez, Diego ; Roca-Ho, Heleia ; Gutiérrez-Agüera, Francisco ;
Molina, Oscar ; Diaz de la Guardia, Rafael ; Torres-Ruiz, Raúl ; Fuster, Jose Luís ; Ballerini, Paola ;
Suessbier, Ute ; Nombela-Arrieta, Cesar ; Bueno, Clara ; Menéndez, Pablo
Abstract: B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure
rates of ￿80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis
with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed
for relapsed/refractory MLLr-B-ALL. MLLr leukemias are characterized by the specific expression of
chondroitin sulfate proteoglycan-4, also known as neuron-glial antigen-2 (NG2). NG2 was recently shown
involved in leukemia invasiveness and central nervous system infiltration in MLLr-B-ALL, and correlated
with lower event-free survival (EFS). We here hypothesized that blocking NG2 may synergize with estab-
lished induction therapy for B-ALL based on vincristine, glucocorticoids, and L-asparaginase (VxL). Using
robust patient-derived xenograft (PDX) models, we found that NG2 is crucial for MLLr-B-ALL engraft-
ment upon intravenous (i.v.) transplantation. In vivo blockade of NG2 using either chondroitinase-ABC
or an anti-NG2-specific monoclonal antibody (MoAb) resulted in a significant mobilization of MLLr-B-
ALL blasts from bone marrow (BM) to peripheral blood (PB) as demonstrated by cytometric and 3D
confocal imaging analysis. When combined with either NG2 antagonist, VxL treatment achieved higher
rates of complete remission, and consequently higher EFS and delayed time to relapse. Mechanistically,
anti-NG2 MoAb induces neither antibody-dependent cell-mediated not complement-dependent cytotoxi-
city. NG2 blockade rather overrides BM stroma-mediated chemoprotection through PB mobilization of
MLLr-B-ALL blasts, thus becoming more accessible to chemotherapy. We provide a proof of concept for
NG2 as a therapeutic target for MLLr-B-ALL.
DOI: https://doi.org/10.1038/s41375-018-0353-0
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-175161
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Lopez-Millan, Belen; Sanchéz-Martínez, Diego; Roca-Ho, Heleia; Gutiérrez-Agüera, Francisco; Molina,
Oscar; Diaz de la Guardia, Rafael; Torres-Ruiz, Raúl; Fuster, Jose Luís; Ballerini, Paola; Suessbier, Ute;
Nombela-Arrieta, Cesar; Bueno, Clara; Menéndez, Pablo (2019). NG2 antigen is a therapeutic target for
MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia, 33(7):1557-1569.
DOI: https://doi.org/10.1038/s41375-018-0353-0
2
Leukemia (2019) 33:1557–1569
https://doi.org/10.1038/s41375-018-0353-0
ARTICLE
Acute lymphoblastic leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute
lymphoblastic leukemia
Belen Lopez-Millan1 ● Diego Sanchéz-Martínez1 ● Heleia Roca-Ho1 ● Francisco Gutiérrez-Agüera1 ● Oscar Molina1 ●
Rafael Diaz de la Guardia1 ● Raúl Torres-Ruiz1,2 ● Jose Luís Fuster3 ● Paola Ballerini4 ● Ute Suessbier5 ●
Cesar Nombela-Arrieta 5 ● Clara Bueno1,6 ● Pablo Menéndez1,6,7
Received: 20 September 2018 / Revised: 15 November 2018 / Accepted: 28 November 2018 / Published online: 11 January 2019
© The Author(s) 2019. This article is published with open access
Abstract
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-
rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and
early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. MLLr leukemias are
characterized by the speciﬁc expression of chondroitin sulfate proteoglycan-4, also known as neuron-glial antigen-2 (NG2).
NG2 was recently shown involved in leukemia invasiveness and central nervous system inﬁltration in MLLr-B-ALL, and
correlated with lower event-free survival (EFS). We here hypothesized that blocking NG2 may synergize with established
induction therapy for B-ALL based on vincristine, glucocorticoids, and L-asparaginase (VxL). Using robust patient-derived
xenograft (PDX) models, we found that NG2 is crucial for MLLr-B-ALL engraftment upon intravenous (i.v.)
transplantation. In vivo blockade of NG2 using either chondroitinase-ABC or an anti-NG2-speciﬁc monoclonal antibody
(MoAb) resulted in a signiﬁcant mobilization of MLLr-B-ALL blasts from bone marrow (BM) to peripheral blood (PB)
as demonstrated by cytometric and 3D confocal imaging analysis. When combined with either NG2 antagonist, VxL
treatment achieved higher rates of complete remission, and consequently higher EFS and delayed time to relapse.
Mechanistically, anti-NG2 MoAb induces neither antibody-dependent cell-mediated not complement-dependent
cytotoxicity. NG2 blockade rather overrides BM stroma-mediated chemoprotection through PB mobilization of MLLr-B-
ALL blasts, thus becoming more accessible to chemotherapy. We provide a proof of concept for NG2 as a therapeutic target
for MLLr-B-ALL.
Introduction
B cell acute lymphoblastic leukemia (B-ALL) is the most
common childhood cancer [1]. Over the past 20 years,
progress in molecular diagnosis, patient stratiﬁcation,
disease biology, therapy, and supportive care has
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considerably improved disease management and clinical
outcome. The backbone of current induction or re-
induction post-relapse treatment protocols is vincristine,
glucocorticoids, and L-asparaginase (VxL), with or with-
out an anthracycline [2], resulting in ∼90% of children
entering complete remission (CR) [3] and eventual cure
rates of ∼80% [4, 5].
Despite the overall progress in treatment, relapsed B-
ALL is the ﬁfth most prevalent pediatric cancer, and B-ALL
remains the most common cause of death from malignancy
in children [6, 7]. Moreover, several B-ALL cytogenetic–
molecular subgroups remain high risk, with 5-year event-
free survival (EFS) and overall survival (OS) rates <30%
[8–10]. B-ALL carrying MLL rearrangements (MLLr-B-
ALL), particularly the t(4;11)+/MLL-AF4+ B-ALL, is of
special interest because of its dismal prognosis, common
therapy refractoriness, and central nervous system (CNS)
inﬁltration [11]. Patients experiencing early relapse or
therapy refractoriness have a poor long-term survival and,
in these cases, the best therapeutic option is hematopoietic
stem cell transplantation (HSCT) following induction into
second remission. However, these patients commonly fail to
achieve a second remission; moreover, current chemother-
apy is associated with morbidity and serious side effects
such as infertility, impaired development, and greater risk of
secondary neoplasms [12, 13]. Thus, innovative directed/
targeted therapeutic approaches are in high demand for
high-risk B-ALL and relapsed/refractory (R/R) B-ALL, and
targeting leukemia-initiating cells and CNS-inﬁltrating
leukemia cells is key to overcome therapy resistance,
relapse, and CNS disease [14, 15].
Chondroitin sulfate proteoglycan-4, also known as
neuron-glial antigen-2 (NG2), is a transmembrane pro-
teoglycan barely expressed in normal hematopoietic cells
[16, 17]. Conversely, ~90% of 11q23/MLLr leukemias
speciﬁcally express NG2, which has been incorporated into
diagnostic workﬂows for leukemia immunophenotyping
because of its predictive value for MLLr [16, 18–21].
Against this background, we recently reported that NG2 is
involved in leukemia invasiveness and CNS inﬁltration in
MLLr-B-ALL, and high levels of NG2 expression in B-
ALL blasts correlates with lower EFS, higher numbers of
circulating blasts and more frequent CNS disease/relapse. In
the present study, we investigated whether NG2 might
represent a therapeutic target for MLLr-B-ALL. Using
robust preclinical patient-derived xenograft (PDX) models,
we show that NG2 antagonists synergize with VxL-based
induction therapy, leading to an extensive mobilization of
MLLr-B-ALL blasts from bone marrow (BM) into periph-
eral blood (PB) where they become more accessible/sensi-
tive to VxL-based chemotherapy, resulting in higher CR
rates (CRRs), and consequently, higher EFS and delayed
time to relapse.
Methods
Patient samples and immunophenotyping
Leukemic samples at presentation were used from n= 5
independent MLLr-B-ALL patients with complete immu-
nophenotypic and molecular/cytogenetic diagnosis. Four
patients were t(4;11)/MLL-AF4+, and one patient was t
(1;11)/MLL-EPS15+. Patients’ mononuclear cells with
>85% CD45lowCD19+CD34+CD10−NG2+ MLLr blasts
were isolated by density gradient centrifugation using
Ficoll-Hypaque (Amersham Biosciences, Uppsala, Swe-
den). MLL/(11q23) status was conﬁrmed by ﬂuorescence
in situ hybridization [22]. Blasts were immunophenotyped
using the monoclonal antibodies (MoAbs) CD45-FITC,
CD19-APC, CD10-PerCP-Cy5.5, CD34-PE-Cy7 (BD
Biosciences, San Jose, CA), and NG2−PE (Beckman,
Barcelona, Spain), and the NG2+ and NG2− blast popula-
tions were isolated by ﬂuorescence-activated cell sorting
(FACS) using a FACSAria cell sorter (BD Biosciences).
The Institutional Review Board of the Hospital Clinic of
Barcelona approved the study, and all patients’ parents gave
written informed consent.
Drugs and antibodies
Vincristine (Selleckchem, Houston, TX, USA) and dex-
amethasone (Sigma-Aldrich, St Louis, MO, USA) were
reconstituted in dimethyl sulfoxide. L-asparaginase (Kidro-
lase®; EUSA Pharma, Oxford, UK) and chondroitinase-
ABC (Ch’ase, Sigma-Aldrich) were reconstituted in
phosphate-buffered saline (PBS) according to the supplier’s
guidelines. Drugs were stored in aliquots at −20 °C. The
clone 9.2.27 MoAb was provided by Abcam (Cambridge,
UK). The clone 7.1 MoAb-producing hybridoma was
kindly provided by Professor Irwin Bernstein (Fred
Hutchinson Cancer Center, Seattle, WA, USA). The anti-
NG2 7.1 MoAb was produced and puriﬁed using standard
methods as previously detailed [18]. All drugs were admi-
nistered by intraperitoneal (i.p.) injection.
PDX models, in vivo treatment, and analysis of
leukemia engraftment
Eight- to-14-week-old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ
mice (NSG; n= 116) housed under pathogen-free condi-
tions were used. The Animal Care Committee of The Bar-
celona Biomedical Research Park approved all experimental
procedures with mice (HRH-17-0045-P2). A total of 1–2 ×
105 iMLLr-B-ALL cells were transplanted intravenously
(i.v) into sublethally (2.25 Gy) irradiated mice as described
[23]. Leukemia engraftment was monitored through weekly
PB analysis, and human grafts were immunophenotyped by
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ﬂow cytometry using HLA-ABC-FITC combined with the
7.1 MoAb indicated above. When human engraftment in PB
was >0.5% (between weeks 6 and 8, depending on the
engraftment kinetics of each patient), mice were homo-
geneously divided into the following treatment groups: (i)
control, (ii) VxL alone, (iii) VxL plus Ch’ase, and (iv) VxL
plus 7.1 MoAb. Treatment schedules were as follows:
vincristine (V, 0.15 mg/kg) once weekly for 2 weeks, dex-
amethasone (x, 5 mg/kg), and L-asparaginase (L, 1000 U/
kg) daily during 5 days for 2 weeks. This standard induction
treatment is known as VxL treatment. Ch’ase (0.06 U/
mouse) and 7.1 MoAb (10 mg/kg) were administered daily
for 7 days (when given alone) or for 14 days (in combi-
nation with VxL). BM aspirates were always performed at
the beginning and end of each treatment. Minimal residual
disease (MRD) was assessed in the BM of each mouse at
the completion of the 15-day treatment schedule. CR was
deﬁned as the presence of ≤1% leukemic cells in BM (0.1%
in PB). Treatment was then stopped and mice were left
untreated for 30 further days to follow-up potential relapse
by weekly analysis of engraftment in PB. Analysis of EFS,
comparing mice treated with VxL vs. VxL plus NG2
blockers, was performed with Kaplan–Meier curves from
the end of the induction treatment (day 15) up to day 45. A
leukemic engraftment in PB >0.5% was established to
deﬁne a relapse event. Mice were sacriﬁced at the end of the
experiment.
In vitro chemoresistance assay
Primary cells were maintained in a humidiﬁed atmosphere
with 5% CO2 at 37 °C. MLLr-B-ALL primary samples cells
were cultured in StemSpam medium (Stem Cell Technol-
ogies, Vancouver, BC, Canada) supplemented with stem
cell factor, FLT3 ligand, interleukin-3 (IL-3) and IL-7 (all
from PeproTech, Rocky Hill, NJ, USA) as described [24].
Bone marrow-derived mesenchymal stromal cells (BM-
MSCs) were obtained, grown, and characterized as exten-
sively described by our group [25–27]. A total of 1 × 105
MLLr-B-ALL blasts were co-cultured in a 96-well plate
with/without 2 × 104 irradiated BM-MSCs for either 30 min
or 24 h. Cells were then exposed to 0.5 or 50 µM VxL for
40 h. Viability (apoptosis) of CD19+ B-ALL blasts was
measured using 7-AAD on a FACSCanto-II cytometer
running FACSDiva software (BD Biosciences) as pre-
viously described [28].
ADCC and CDC assays
Antibody-dependent cell-mediated (ADCC) and
complement-dependent cytotoxicity (CDC) assays were
performed to directly address the anti-NG2-mediated cyto-
toxicity, as previously described [29, 30]. Brieﬂy, target
cells (SEM (NG2+CD20−) and Daudi (NG2-CD20+)) were
pre-incubated with anti-NG2 (7.1 MoAb) or anti-CD20
(Rituximab) MoAb at 10 μg/mL for 30 min at 37 °C. Then,
they were incubated with either peripheral blood mono-
nuclear cells (PBMCs) at 10:1 effector:target ratio or 10%
human AB serum to induce ADCC and CDC, respectively.
Cytotoxicity was determined 4 and 24 h later by analyzing
the proportion of AnnexinV+/7-ADD+ by FACS. PBMCs
were labeled with 3 µM eFluor to distinguish them from
target cells. Speciﬁc cell death was determined relative to
basal cell death in the absence of MoAb (consistently <5%).
3D confocal microscopy of BM
3D imaging of mouse femoral BM cavities was performed
as previously described [31]. Brieﬂy, bones were collected,
ﬁxed for 6 h in PBS/2% paraformaldehyde (PFA) at 4 °C,
and dehydrated by incubation in PBS/30% sucrose for 72 h.
Bones were then embedded in OCT, and snap frozen in
liquid nitrogen. Thick slices (400–700 µm) of BM were
obtained by iteratively sectioning both sides of the femur
using a cryostat until the BM cavity was bilaterally exposed.
The remaining OCT embedding medium was removed by
washing BM slices three times in PBS for 5 min, followed
by an additional ﬁxation step in 2% PFA for 2 h at 4 °C.
Slices were blocked overnight in blocking buffer (0.2%
Triton X-100, 1% BSA, 10% Donkey serum in PBS) and
incubated with primary antibodies against endomucin
(CD105, Santa Cruz Biotechnology, Dallas, TX, USA),
huCD45, and collagen (Abcam) in blocking solution for 72
h at 4 °C. After repeated washing in PBS (3 × 2 h) slices
were incubated with a secondary antibody cocktail solution
(Jackson ImmunoResearch (Cambridge, UK and Invitro-
gen) including 2 µm 4′,6-diamidino-2-phenylindole (DAPI)
for an additional 72 h at 4 °C. After successive washing
steps, immunostained slices were optically cleared through
overnight incubation in RapiClear 1.52 (Sunjinlab, Hsinchu
City, Taiwan). The slices were then mounted on glass slides
for imaging using a SP8 Leica confocal microscope
equipped with hybrid detectors using ×10 (HCX-PL-
FLUOTAR) and ×20 (HC-PL-APO-CS2) objectives. Ima-
ging data were analyzed and videos assembled using the
Imaris v8.2 software (Bitplane AG). Supplemental videos
may be found in Supplementary data available with the
online version of this article.
Statistical analysis
Data are expressed as mean ± SEM of independent experi-
ments unless otherwise speciﬁed. Statistical comparisons
were performed using either paired or unpaired Student’s t
test, as appropriate. For MRD studies, data are expressed as
median (range) and signiﬁcant differences were analyzed by
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia 1559
the median test. CRRs were statistically compared using
Pearson’s χ2 test and EFS curves were compared using the
log-rank test. Analyses were performed using GraphPad
Prism v6.0 (GraphPad Software Inc., La Jolla, CA, USA) or
SPSS software (SPSS version 22, Chicago, IL, USA). Sta-
tistical signiﬁcance was deﬁned as a p value < 0.05.
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Results
NG2 blockage does not elicit cytotoxicity of MLLr-B-
ALL blasts but results in in vivo robust blast
mobilization into PB
We ﬁrst interrogated the ability of FACS-sorted NG2+ and
NG2− diagnostic leukemic blasts to reproduce the B-ALL
phenotype by engrafting in NSG mice. When equal num-
bers of NG2+ and NG2− B-ALL primary blasts (105 cells/
patient, n= 4) were intravenously (i.v.) infused into NSG
mice, engraftment levels after 8 weeks were 3.5-fold higher
in the PB of mice transplanted with NG2+ than in equiva-
lent mice transplanted with NG2− blasts (11.2 ± 1.8% vs.
3.2 ± 1.5%, p= 0.008) (Fig. 1a, left and middle panels).
Overnight in vitro treatment of NG2+ B-ALL blasts with
either Ch’ase (0.1U/ml) or anti-NG2 MoAb (either 7.1 (0.7
µg/ml) or 9.2.27 (100 µg/ml) clone) abolished their
engraftment after i.v. transplantation (12 ± 1.7% vs. <2%, p
< 0.001) (Fig. 1a, right panel). Importantly, clinical data
from MLLr-BCP-ALL infants (n= 55) uniformly enrolled
in the Interfant treatment protocol reveals that patients with
refractory or relapsed disease initially had at diagnosis 28%
more NG2-expressing blasts than those patients not
experiencing relapse (53% vs. 41%, p > 0.05). This suggests
that NG2 plays a role in vivo in the propagation of MLLr-B-
ALL cells.
We then assessed in vitro and in vivo whether anti-NG2
(7.1 MoAb) effectively eliminates NG2+ MLLr-B-ALL
blasts. In vitro, anti-NG2 treatment was unable to activate
effector mechanisms including CDC (Fig. 2a, b) and ADCC
(Fig. 2c), resulting in no cytotoxicity of NG2-expressing
MLLr-B-ALL cells in 4- and 24-h assays. As a control,
Rituximab (anti-CD20 MoAb) effectively activated both
CDC and ADCC cytotoxicity mechanisms to eliminate
Daudi cells (Fig. 2). We further addressed whether NG2
blockage elicits cytotoxicity in vivo, thus impacting the
engraftment dynamics of MLLr-B-ALL blasts in PDX
models (Fig. 1b). A total of 105 NG2+MLLr-B-ALL cells
(n= 4 patients) were i.v. transplanted and, once PB
engraftment reached >0.5%, mice were daily i.p. treated
with the NG2 antagonist Ch’ase (0.06 U/mouse) or anti-
NG2 7.1 MoAb (10 mg/kg/mouse) for 7 days (Fig. 1b). In
line with the in vitro data, NG2 blockage in vivo failed to
reduce tumor burden (Fig. 1c). However, when we com-
pared vehicle-treated primografts with primografts treated
with either NG2 antagonist after completion of the treat-
ment, we found that treatment with NG2 antagonists sig-
niﬁcantly reduced leukemic burden in BM that was
accompanied by a massive leukemia inﬁltration in PB (p <
0.01; Fig. 1c, d). Importantly, PDX models reproduced the
immunophenotype of the de novo primary leukemia, and
blasts recovered from primografts treated with NG2
blockers were mainly NG2− (Fig. 1e). These results show
that blocking NG2 in vivo mobilizes MLLr-B-ALL blasts to
PB. This coupled to our previous data [18], reporting
similar engraftment levels of NG2+ MLLr-B-ALL blasts
when directly delivered intra-BM, suggest that NG2 reg-
ulates mobilization to and engraftment in the BM.
In order to conﬁrm FACS-based quantiﬁcations, we
employed advanced protocols for in situ 3D BM imaging,
which allows to visualize the presence and distribution of
the human graft within the native BM microenvironment of
control and anti-NG2-treated mice at the end of treatment.
Engrafted human B-ALL cells were labeled by immunos-
taining against huCD45 (Fig. 3a). Consistent with our
FACS data, we repeatedly observed the presence of large
tissue volumes devoid of human cells, but ﬁlled with
murine hematopoietic cells in the BM of anti-NG2-treated
mice. These patches devoid of huCD45+ cells were sub-
stantially smaller and almost absent in control BM (Fig. 3a,
Suppl Videos 1 and 2), thereby conﬁrming that NG2
blockage efﬁciently induces egress and mobilization of BM
MLLr-B-ALL leukemic cells.
NG2 antagonists synergize with VxL therapy and
render higher CR rates and EFS in preclinical PDX
models of MLLr-B-ALL
BM stroma confers chemoresistance to leukemic cells in a
variety of hematological malignancies [32, 33]. We there-
fore ﬁrst tested in vitro whether BM-MSCs also protect
NG2+ MLLr-B-ALL primary blasts from VxL. NG2+
blasts pre-exposed to BM-MSC for 30 min or 24 h dis-
played ∼20% or ∼40% increased resistance to VxL,
respectively, indicating a BM stroma-mediated chemopro-
tection of MLLr-B-ALL blasts to induction therapy
(Fig. 3b). Mobilization of leukemic cells from BM to PB is
clinically desirable because circulating blasts become more
accessible (and sensitive) to cytotoxic treatments due, in
Fig. 1 In vivo blockade of NG2 results in the robust mobilization of
MLLr-B-ALL blasts into PB. a Left, experimental design of the
in vitro treatment with NG2 antagonists. Middle, engraftment capacity
of NG2+ or NG2− MLLr-B-ALL blasts 8 weeks after i.v. transplan-
tation. Right, overnight in vitro exposure of NG2+ blasts to the NG2
antagonists Ch’ase, 7.1 MoAb, or 9.2.27 MoAb abolishes their
engraftment potential [18]. b Experimental design of the in vivo
treatment with NG2 antagonists. c Monitoring of the levels of leu-
kemic grafts in PB and BM before (day 0) and after (day 7) the
indicated treatments. Each line represents the same mouse before and
after treatment. d Levels of leukemic grafts in BM (top panel) and PB
(bottom panel) after the indicated in vivo treatments. Results are
shown as mean ± SEM, relative to day 0 (before treatment). e Repre-
sentative FACS plots showing the identical leukemia NG2+ phenotype
in both diagnostic samples and primografts. The right panel shows the
in vivo effectiveness of the 7.1 MoAb, which abolishes NG2
expression in blasts recovered from primografts. n, 8–12 mice/group
from three different patients. *p < 0.05; **p < 0.01; ****p < 0.0001
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part, to their detachment from the chemoprotective BM
niche [34–36]. Therefore, we next tested whether mobili-
zation of MLLr-B-ALL blasts to PB with the NG2
antagonist Ch’ase (Fig. 4) or 7.1 MoAb (Fig. 5) synergizes
with VxL treatment in PDX models of MLLr-B-ALL. To
do this, engrafted PDXs were treated with vehicle, VxL
alone, VxL plus Ch’ase, or VxL plus 7.1 MoAb, and CR
(MDR <1% leukemic cells in BM (approx. <0.1% in PB)
was assessed at completion of the treatment (day 15)). Mice
were then left untreated for 30 days and relapse and EFS
Fig. 2 Anti-NG2 MoAb lacks both cellular-mediated (ADCC) and
complement-mediated (CDC) cytotoxicity. a CD19, CD20, and
NG2 surface immunophenotype in Daudi (control) and SEM-NG2
cells. b, c CDC (b) and ADCC (c) assays at 4 h (left panels) and 24 h
(right panels) with Daudi and SEM-NG2 cells using both anti-NG2
(7.1 MoAb) and anti-CD20 (Rituximab) (n= 2). CT: no MoAb con-
trol. Human AB serum was used for CDC and human PBMCs were
used for ADCC. *p < 0.05; **p < 0.01; ***p < 0.001
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were determined (Fig. 4a). In contrast to vehicle-treated
mice, VxL treatment was highly efﬁcient and engrafted
PDXs treated with two cycles of VxL (14 days) showed a
massive decrease in leukemia burden in both BM and PB
(Figs. 4b, 5a). Moreover, despite comparable engraftment
levels (∼24%) in BM at the time of treatment initiation (day
0) (Figs. 4c, 5b), the levels of B-ALL engraftment in BM at
the end of treatment (day 15) was ∼3-fold lower when
Fig. 3 a In situ 3D microscopy imaging of BM from primografts
treated with NG2 antagonists. Representative images of large tissue
volumes from the femoral diaphysis of transplanted mice treated with
the vehicle (CTRL, left panels), or with 7.1 MoAb for 7 days (NG2
blockage, right panels). Large DAPI+ tissue regions depleted of
huCD45+ cells are only observed in the BMs from mice treated with
7.1 MoAb. See also Supplementary Videos 1 and 2. b BM-MSCs
protect MLLr-B-ALL cells against VxL chemotherapy (n= 2)
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either Ch’ase (0.8% vs. 2.2%, Fig. 4b, d) or 7.1 MoAb
(1.3% vs. 2.95%, Fig. 5a, c) were co-administered with
VxL. As a consequence, the rate of animals achieving CR
increased 2-fold when NG2 antagonists were co-
administered with VxL: 63% vs. 33% for Ch’ase (Fig. 4d)
and 46% vs. 20% for 7.1 MoAb (Fig. 5c). To further assess
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the potential clinical impact of the lower levels of MRD and
higher CR rates, treatment was removed and PDXs were
followed-up for a 30-day period. Importantly, 45-day EFS
was higher in the group treated with either Ch’ase (65% vs.
31%, Fig. 4e) or 7.1 MoAb (55% vs. 40%, Fig. 5d) than
with VxL alone. Accordingly, at the time of sacriﬁce, mice
in the VxL-alone group had 50% higher leukemic burden
than those receiving VxL combined with NG2 antagonists
(Fig. 4f). Collectively, these results indicate that NG2
blockade overrides BM stroma-mediated chemoprotection
through PB mobilization of MLLr-B-ALL blasts, which
consequently are more accessible to conventional che-
motherapy (Fig. 6).
Discussion
There has been considerable progress in the past two dec-
ades in understanding the biology of B-ALL, which toge-
ther with better molecular diagnosis, patient stratiﬁcation,
and therapy, has substantially improved clinical outcomes.
VxL, with or without an anthracycline [2], is currently the
backbone of induction (or re-induction post-relapse) treat-
ment protocols with ∼90% of children entering CR [3] and
an eventual 5-year cure rate of ∼80% [4, 5]. Nevertheless,
relapsed or refractory B-ALL (R/R B-ALL) is still common
and remains non-curable [6, 7]. Moreover, age <1 year and
MLLr are two major adverse prognostic factors in B-ALL.
Accordingly, MLLr-B-ALL patients remain high-risk with
5-year EFS and OS rates <30% [8–10]. The t(4;11)+/MLL-
AF4+ B-ALL is of special interest owing to its extremely
short latency and dismal prognosis, common therapy
refractoriness, and CNS involvement [11]. In R/R B-ALL
patients, the best therapeutic options are currently: (i) HSCT
following induction into second CR, but they frequently fail
to achieve a second remission; or (ii) anti-CD19-targeted
immunotherapies, which have shown very promising out-
comes although disease-free remissions are usually main-
tained for limited time [37–39]. Furthermore, current
chemotherapy is associated with morbidity and serious side
effects such as infertility, impaired development, and
greater risk of secondary neoplasms [12, 13]. Thus, new
targeted therapeutic approaches are urgently needed for de
novo high-risk B-ALL and R/R B-ALL.
Here we analyzed whether NG2, a surface antigen
exclusively expressed in 11q23/MLLr leukemias, represents
a target for MLLr-B-ALL. The therapeutic interest in tar-
geting NG2 in MLLr R/R B-ALL is based on recent ﬁnd-
ings involving NG2 in leukemia invasiveness, CNS
inﬁltration, and clinical outcome. Indeed, high expression of
NG2 in B-ALL blasts has been associated with lower EFS,
hyperleukocytosis, and more common relapse [18]. Our
robust preclinical PDX models coupled to in situ 3D con-
focal imaging of native BM revealed that NG2 is crucial for
MLLr-B-ALL engraftment upon i.v. transplantation, and
that in vivo blockade of NG2 using either a speciﬁc inhi-
bitor Ch’ase or an anti-NG2-speciﬁc antibody results in an
extensive mobilization of MLLr-B-ALL blasts from BM to
PB. These ﬁndings are in line with previous studies impli-
cating NG2 antigen with MLLr leukemia invasiveness and
migration [18], and are consistent with the known biology
of NG2. Importantly, anti-NG2 MoAb does not activate
either ADCC or CDC cytotoxicity pathways, thus resulting
in a lack of cytotoxicity in vitro and in vivo, which further
supports the role of NG2 in regulating MLLr-B-ALL blast
mobilization to and engraftment in the BM.
NG2 is a transmembrane proteoglycan barely expressed
in normal hematopoietic cells [16, 17], but speciﬁcally
expressed in ~90% of MLLr acute leukemias [16, 17].
Accordingly, it has been incorporated into diagnostic
workﬂows for leukemia immunophenotyping due to its
predictive value for MLLr [16, 18–21]. NG2 is a single-pass
type I transmembrane protein that has a very large extra-
cellular domain and short transmembrane and intracyto-
plasmic domains [40, 41]. The large extracellular domain
consists of three subdomains known as D1–3 that signal
upon interaction with multiple extracellular matrix compo-
nents, including laminins (binding through D1) collagen
types II, V, VI, and ﬁbronectin (binding through D2), and
with tenascin, galectins, and lectins such as P-selectin and
α3β1 integrin (binding through D1) [41–43]. It is therefore
likely that the NG2 molecule has an important role in the
anchoring of blasts to the BM niche, such that the loss of
such a cellular interaction results in detachment of MLLr
blasts from the BM and their subsequent mobilization to
PB. This scenario is similar to that of molecules commonly
employed in clinical practice for the mobilization of either
hematopoietic progenitors or acute myeloid leukemia
Fig. 4 In vivo treatment with Ch’ase sensitizes blasts to VxL, ren-
dering higher CR rates and higher EFS in preclinical PDX models of
MLLr-B-ALL. a Complete experimental design of the preclinical PDX
models detailing in vivo treatments with VxL and NG2 antagonists.
After 2 complete cycles of VxL chemotherapy, MRD/CR was eval-
uated and relapse was followed-up for up to 30 days. b Monitoring of
the levels of leukemic engraftment in PB and BM for the indicated
treatments. PB engraftment was analyzed weekly. BM leukemic
engraftment was analyzed using BM aspirates at the end of VxL ±
Ch’ase treatment (day 15) and at the end of the follow-up period (day
50). Each line represents the same mouse before and after treatment. c
Levels of leukemia engraftment in BM at treatment initiation (day 0)
for VxL or VxL+ Ch’ase mice cohorts. d BM levels of MRD at the
end of two cycles of VxL ± Ch’ase (day 15). Each dot represents a
single mouse. A mouse is considered in CR when the % of blasts in
BM <1% (blue horizontal dotted line). The light blue bars represent the
proportion of mice in CR (right Y-axis) for VxL and VxL+ Ch’ase
(n= 18 mice/group). e Kaplan–Meier survival curves for 45 days EFS
(n= 16 mice). f Leukemic burden in BM at sacriﬁce. *p < 0.05; n.s.:
no signiﬁcant differences
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(AML) blasts into PB, such as granulocyte-colony-
stimulating factor or plerixafor [44–46].
The interaction of leukemic cells with the BM micro-
environment in functional niches is a major mechanism
underlying leukemia maintenance by favoring leukemic cell
growth and clonal evolution of malignant cells, ultimately
resulting in therapy resistance and relapse [47–52]. Thus,
PB-mobilized MLLr-B-ALL blasts not only become more
accessible but might also be sensitized to conventional
chemotherapy by overriding BM stroma-mediated chemo-
protection, a major mechanism underlying refractoriness to
chemotherapy [53, 54]. Our data further show that MLLr-B-
ALL blasts mobilized to PB with NG2 antagonists do in fact
become sensitized to conventional chemotherapy (VxL) as
demonstrated by lower levels of MRD and therefore higher
rates of CR at treatment completion, resulting in higher EFS
and delayed time to relapse. Previous preclinical studies
have successfully used an anti-NG2 MoAb to signiﬁcantly
reduce both adhesion-induced cell spreading and
anchorage-independent growth of melanoma cells [55].
Conversely, ectopic expression of NG2 in NG2-null human
melanoma cells led to enhanced tumor spreading, unequi-
vocally implicating NG2 as a major regulator of migration
and invasion in melanoma [56]. Of note, both NG2+ and
NG2− cells are found in engrafted mice, suggesting a NG2
regulation in response to a homeostatic adaptation of MLLr
Fig. 5 In vivo treatment with 7.1 MoAb sensitizes blasts to VxL,
rendering higher CR rates and higher EFS in preclinical PDX models
of MLLr-B-ALL. a Monitoring levels of leukemic grafts in PB and
BM for the indicated treatments. PB engraftment was analyzed
weekly. BM leukemic engraftment was analyzed using BM aspirates at
the end of VxL ± 7.1 MoAb treatment (day 15) and at the end of
follow-up period (day 50). Each line represents the same mouse before
and after treatment. b Levels of leukemia engraftment in BM at
treatment initiation (day 0) for VxL or VxL ± 7.1 MoAb mice cohorts.
c BM levels of MRD at the end of two cycles of VxL ± 7.1 MoAb (day
15). Each dot represents a single mouse. A mouse is considered in CR
when the % of blasts in BM <1% (blue horizontal dotted line). The
light blue bars represent the proportion of mice in CR (right Y-axis) for
VxL and VxL ± 7.1 MoAb. d Kaplan–Meier survival curves for
45 days EFS (n= 10–11 mice in each group). *p < 0.05; n.s.: no
signiﬁcant differences
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leukemic cells. This further supports NG2-targeted treat-
ment (along with current chemotherapy) as a promising
adjuvant therapy to disturb such homeostatic adaptation of
MLLr blasts.
This is the ﬁrst study targeting NG2 in human leukemias
and provides a proof-of-concept preclinical model for NG2
as a therapeutic target for MLLr-B-ALL (Fig. 6). Because
NG2 is a malleable marker with enhanced expression in
blasts inﬁltrating extramedullar hematopoietic sites [18], we
propose that a MoAb-based or chimeric antigen receptor
(CAR) T-cell-based immunotherapy approaches will beneﬁt
current treatment of de novo or R/R MLLr-B-ALL patients.
In addition, over 80% of leukemic blasts in MLLr AML are
NG2+, suggesting that MLLr AML may also be a candidate
high-risk leukemia for NG2 targeting. As a note of caution,
we must bear in mind that any new immunotherapy despite
being directed against a speciﬁc antigen not expressed in
healthy tissues/cells could be in the long-term accompanied
by potential secondary events, not anticipated a priori. CAR
T cells or bispeciﬁc monoclonal antibodies-based clinical
trials have revealed mechanisms of immune escape and
even “on-target off-tumor toxicities” toxicities [57].
Therefore, future preclinical studies and phase I clinical
trials will deﬁnitively determine the implementation of a
NG2-based immunotherapy for MLLr acute leukemias.
Although Ch’ase and 7.1 MoAb render a very similar effect,
a strategy based on a MoAb is expected to display less on-
target off-tumor toxicity.
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Fig. 6 A proposed mechanism of action for NG2 antagonists. NG2 is
well established to bind to common components of the extracellular
matrix including collagen [40, 41, 57]. This supports a model in which
in vivo blockade of NG2 may disrupt the interaction between MLLr-
B-ALL blasts and BM stroma, promoting the mobilization of MLLr-B-
ALL blasts into PB, thus overriding BM stroma-mediated chemo-
protection and making leukemic cells more accessible (sensitive) to
conventional chemotherapy
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